*Update Moving forward, watchlist released for free every Sunday night will only list the stocks that I am watching. Entry/exit zones (along w/ charts) will be shared occasionally with individuals who are signed up for the newsletter. If you're not on my mailing list; sign up below. It is free.
Did you miss our $SWHC pick that provided subscribers with a gain of about +40%+? How about our speculative $NXTD pick, with a gain of over +60%? Don't miss out on the next. Become a premium member today!
I love, love, love wall street rumors. More often than not, it provides volatility and range for the stocks spoken about. With that said, earlier today; Bloomberg.com reported that pharmaceutical giant Pfizer is close to an agreement to buy Medivation in a $14 billion dollar deal. If the deal goes through, Pfizer will have Xtandi, a prostate-cancer treatment drug, to add to its list of blockbuster. $MDVN closed on Friday at $67.16 representing a market value of a little over $11 billion. $PFE closed at $34.98 and is currently a few points off its 52 weeks high. Tomorrow can prove to provide a trading opportunity for both stocks. Plan your trade and trade your plan.
This watchlist is for information and illustrative purposes only. It is not, and should not be regarded as investment advice or as a recommendation to buy, sell and/or hold any securities mentioned above. All investments carry risk, there are no guarantees. Investors should consult with their advisers with respect to their investments.
This website is for information and illustrative purposes only. It is not, and should not be regarded as investment advice or as a recommendation to buy, sell and/or hold any securities mentioned. All investments carry risk, there are no guarantees. Investors should consult with their advisers with respect to their investments. Please read our full disclaimer here.
CFTC RULE 4.41 – HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.